Patent application number | Description | Published |
20080317726 | Proteases for Pharmaceutical Use - The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from | 12-25-2008 |
20090047266 | Lipases for Pharmaceutical Use - The pharmaceutical use of lipases related to a variant of the | 02-19-2009 |
20090104126 | Sulfamate Compounds and Uses Thereof - A sulfamate compound corresponding to Formula I | 04-23-2009 |
20100034797 | Lipase Variants for Pharmaceutical Use - The pharmaceutical use of lipases related to the | 02-11-2010 |
20100135978 | Proteases for Pharmaceutical Use - The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from | 06-03-2010 |
20100322915 | Protease Variants for Pharmaceutical Use - The invention relates to novel variants of a protease derived from | 12-23-2010 |
20110110910 | Proteases for Pharmaceutical Use - The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from | 05-12-2011 |
20110158976 | Enzymes for pharmaceutical use - The pharmaceutical use of proteases related to a protease derived from | 06-30-2011 |
20120207741 | Enzymes For Pharmaceutical Use - The pharmaceutical use of proteases related to a protease derived from | 08-16-2012 |
20140302000 | PHARMACEUTICAL COMPOSITIONS OF LIPASE-CONTAINING PRODUCTS, IN PARTICULAR OF PANCREATIN - Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans. | 10-09-2014 |